A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : CDDP

Search Conditions:
Search Keyword : CDDP
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: CDDP
Appearance Frequency: 894 time(s)
Long forms: 230

Display Settings:
[Display Entries]
Long Form, 100 entries
    (Appearance freq, Descending)
Long Form, all entries
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
cis-diamminedichloroplatinum
(516 times)
Neoplasms
(294 times)
5-FU (34 times)
ADM (14 times)
MMC (14 times)
1978 Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man.
cis-dichlorodiammineplatinum
(79 times)
Neoplasms
(35 times)
ADM (9 times)
5-FU (8 times)
ROS (4 times)
1978 Variables for predicting serious toxicity (vinblastine dose, performance status, and prior therapeutic experience): chemotherapy for metastatic testicular cancer with cis-dichlorodiammineplatinum(II), vinblastine, and bleomycin.
Compound Danshen Dripping Pill
(32 times)
Complementary Therapies
(13 times)
AMI (5 times)
DR (4 times)
RCTs (4 times)
2004 Study of the determination and pharmacokinetics of Compound Danshen Dripping Pills in human serum by column switching liquid chromatography electrospray ion trap mass spectrometry.
cells induced by cisplatin
(4 times)
Neoplasms
(3 times)
MMP (1 time)
ROS (1 time)
VDAC1 (1 time)
1996 Involvement of intracellular glutathione in induction of apoptosis by cisplatin in a human pharyngeal carcinoma cell line.
chemotherapy and low-dose cisplatin
(4 times)
Neoplasms
(3 times)
5-FU (1 time)
CP (1 time)
HAIC (1 time)
2002 [A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer].
chemotherapy drug cis-diamminedichloroplatinum(II)
(4 times)
Neoplasms
(2 times)
CMHA (2 times)
3-MA (1 time)
5-FU (1 time)
2000 Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
combined with low-dose cisplatin
(4 times)
Neoplasms
(2 times)
ESCC (1 time)
IMRT (1 time)
LCAF (1 time)
2003 Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
conserved DNA-derived polymorphism
(4 times)
Molecular Biology
(2 times)
SCoT (4 times)
AFLP (2 times)
ITAP (2 times)
2015 Characterization of genetic diversity in chickpea using SSR markers, Start Codon Targeted Polymorphism (SCoT) and Conserved DNA-Derived Polymorphism (CDDP).
1-p-chlorophenyl-4,4-dimethyl-5-diethylamino-1-penten-3-one
(3 times)
Biochemistry
(2 times)
--- 1989 1-p-chlorophenyl-4,4-dimethyl-5-diethylamino-1-penten-3-one hydrobromide, a sulfhydryl-specific compound which reacts irreversibly with protein thiols but reversibly with small molecular weight thiols.
10  cancer were treated with combination chemotherapy including cisplatin
(3 times)
Neoplasms
(2 times)
beta 2-MG (1 time)
Ccr (1 time)
1988 [Hypomagnesemia following chemotherapy of disseminated testicular tumors].
11  chemoradiotherapy with S-1 and cisplatin
(3 times)
Neoplasms
(3 times)
CR (1 time)
DOX (1 time)
MTD (1 time)
1999 Acquisition of multidrug resistance in osteosarcomas, analyzed by doxorubicin binding assay, and histologic response to chemotherapy.
12  combined with daily administration of low dose cisplatin
(3 times)
Neoplasms
(3 times)
GBM (1 time)
IORT (1 time)
1996 [Radiotherapy combined with daily administration of low dose cisplatin for head and neck cancer].
13  cancer patients who presented with nephrotoxicity due to cisplatin
(2 times)
Antineoplastic Agents
(2 times)
--- 1998 [A clinical phase II trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
14  carcinoma with bone metastasis responding to concurrent TS-1/low-dose cisplatin
(2 times)
Antineoplastic Agents
(1 time)
--- 2004 [A case of hepatocellular carcinoma with bone metastasis responding to concurrent TS-1/low-dose cisplatin (CDDP) therapy and radiotherapy].
15  case of acute and delayed emesis induced by cisplatin
(2 times)
Pharmacy
(1 time)
DEX (1 time)
2006 [Comparison of dexamethasone 8 mg and 16 mg for the prevention of acute and delayed cisplatin-induced emesis in patients with lung cancer].
16  CDDP-liposome
(2 times)
Neurosurgery
(1 time)
EB (1 time)
1996 Targeting chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyperthermia.
17  CDHP and cisplatin
(2 times)
Neoplasms
(2 times)
5-FU (1 time)
CDHP (1 time)
DNA-PKcs (1 time)
1986 Effects on the monocyte-macrophage system and antitumor activity against L1210 leukemia of cis-bis-cyclopentenecarboxylato-trans-R,R-1,2-diaminocyclohexane -platinum (II) encapsulated in multilamellar vesicles.
18  cis-DDP
(2 times)
Biology
(1 time)
SH (1 time)
1986 [Sensitivity of mice to systemic hyperthermia: effect of the transplantation of ascites tumor cells modified by preheating, and by an injection of CDDP or interferon].
19  cis-DDPlatinum
(2 times)
General Surgery
(2 times)
5-FU (2 times)
ADM (2 times)
CPM (2 times)
1987 Comparative study on nude mice isotope assay (NM-IA) and subrenal capsule assay (SRCA) sensitivity tests of anticancer agents.
20  cis-Diamminedichloroplatinum/cisplatin
(2 times)
Neoplasms
(2 times)
5-FU (1 time)
ESCC (1 time)
FUBP1 (1 time)
2018 Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancers.
21  combination with fixed doses of cisplatin
(2 times)
Neoplasms
(2 times)
GEM (1 time)
MTD (1 time)
MTDs (1 time)
1997 Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
22  combined chemotherapy with S-1 and cisplatin
(2 times)
Antineoplastic Agents
(2 times)
CT (1 time)
EC (1 time)
2005 [Preoperative combination chemotherapy with TS-1 is effective in a case gastric cancer with peritoneal dissemination].
23  Combined Diet Dialysis Program
(2 times)
Nephrology
(2 times)
THD (1 time)
2014 The incremental treatment of ESRD: a low-protein diet combined with weekly hemodialysis may be beneficial for selected patients.
24  combined docetaxel, cisplatin
(2 times)
Gastroenterology
(2 times)
5-FU (1 time)
DCF (1 time)
HCC (1 time)
2009 Successful treatment of multiple lung metastases of hepatocellular carcinoma by combined chemotherapy with docetaxel, cisplatin and tegafur/uracil.
25  combined use of hyperthermia and either cisplatin
(2 times)
Urology
(1 time)
ADM (1 time)
CY (1 time)
1992 Responses of tumour cell lines implanted onto the chorioallantoic membrane of chick embryo to anticancer agents in combination with hyperthermia.
26  confirmed lung cancer were treated with cis-platinum
(2 times)
Neoplasms
(2 times)
BAI (2 times)
1984 [Effects of infusion of cis-platinum into the bronchial artery in lung cancer].
27  consecutive daily administration of cisplatin
(2 times)
Neoplasms
(1 time)
5-FU (2 times)
HCC (1 time)
mPVTT (1 time)
1998 Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer.
28  constrained differential dynamic programming
(2 times)
Environmental Health
(2 times)
GA (2 times)
2002 Dynamic optimal ground water remediation including fixed and operation costs.
29  cytotoxicity induced by cisplatin
(2 times)
Cell Biology
(1 time)
CPT (1 time)
ERK (1 time)
MEK (1 time)
1998 Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines.
30  1-cyclobutanedicarboxylic acid group at the two chlorine positions of cisplatin
(1 time)
Antineoplastic Agents
(1 time)
DLF (1 time)
1990 [Development of carboplatin].
31  B-cells to apoptosis induced by cisplatin
(1 time)
Neoplasms
(1 time)
MM (1 time)
2010 Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis.
32  C, vindesine and cisplatin
(1 time)
Antineoplastic Agents
(1 time)
--- 2000 [Effectiveness of docetaxel plus cisplatin in large cell lung cancer showing little response to prior chemotherapy with MVP].
33  c-myb antisense phosphorothioate oligodeoxynucleotides ((S)ODNs) and cisplatin
(1 time)
Neoplasms
(1 time)
--- 1996 Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.
34  CAD gene transfer to L cells treated with cisplatin
(1 time)
Neoplasms
(1 time)
CAD (1 time)
SCC (1 time)
2004 Combined treatment of cisplatin and overexpression of caspase-activated deoxyribonuclease (CAD) promotes apoptosis in vitro and in vivo.
35  cadmium and cancer therapy with cisplatin
(1 time)
Hematology
(1 time)
Cd (1 time)
Co (1 time)
EPO (1 time)
2000 Cadmium and platinum suppression of erythropoietin production in cell culture: clinical implications.
36  can be detected using host cell reactivation of cisplatin
(1 time)
Biochemistry
(1 time)
A-G (1 time)
GG (1 time)
XP (1 time)
1989 Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA.
37  can induce recoverable renal damage and induce apoptosis, cisplatin
(1 time)
Biochemistry
(1 time)
MK (1 time)
2000 Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of Bcl-2 expression by Midkine.
38  can prevent renal dysfunction due to cisplatin
(1 time)
Pulmonary Medicine
(1 time)
Ccr (1 time)
Cr (1 time)
FENa (1 time)
1992 [Prophylactic effect of ulinastatin on cisplatin-induced renal disorders in lung cancer patients].
39  can reduce side effects of cisplatin
(1 time)
Pharmacology
(1 time)
Se (1 time)
2008 Attenuating the toxicity of cisplatin by using selenosulfate with reduced risk of selenium toxicity as compared with selenite.
40  cancer have described responses to cisplatin
(1 time)
Neoplasms
(1 time)
--- 1993 Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.
41  cancer killing efficacy of standard chemotherapeutic agents such as cisplatin
(1 time)
Medicine
(1 time)
--- 2012 Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy.
42  cancer patients is radiation therapy and concurrent cisplatin
(1 time)
Pharmacology
(1 time)
HT (1 time)
2017 Tumor microenvironment determines response to a heat-activated thermosensitive liposome formulation of cisplatin in cervical carcinoma.
43  cancer patients who had had no prior chemotherapy with cisplatin
(1 time)
Antineoplastic Agents
(1 time)
PTX (1 time)
2004 [Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
44  cancer patients who received chemotherapy including cisplatin
(1 time)
Antineoplastic Agents
(1 time)
APR (1 time)
2012 [Antiemetic effect of aprepitant in cancer patients receiving Cisplatin regimen].
45  cancer successfully treated by low-dose cisplatin
(1 time)
Antineoplastic Agents
(1 time)
5-FU (1 time)
THP (1 time)
2000 [A case of nonresectable scirrhous type gastric cancer successfully treated by low-dose cisplatin (CDDP), 5-fluorouracil (5-FU) and pirarubicin (THP)].
46  cancer treated with intrapericardial and intrapleural infusion of cisplatin
(1 time)
Antineoplastic Agents
(1 time)
--- 2006 [A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)].
47  cancer who received NAC with S-1 and cisplatin
(1 time)
Antineoplastic Agents
(1 time)
CR (1 time)
NAC (1 time)
PD (1 time)
2016 [Treatment Outcomes of Advanced Gastric Cancer after Neoadjuvant Chemotherapy with S-1 and Cisplatin].
48  cancer with peritoneal dissemination maintained on TS-1, cisplatin
(1 time)
Antineoplastic Agents
(1 time)
--- 2006 [A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL].
49  cancer, and the established antitumour agent cis-platinum
(1 time)
Antineoplastic Agents
(1 time)
NMF (1 time)
1986 The antitumour effect and toxicity of cis-platinum and N-methylformamide in combination.
50  cancer, and treated with cisplatin
(1 time)
Gastroenterology
(1 time)
HNC (1 time)
1999 A case of hyperosmolar nonketotic coma occurring during chemotherapy using cisplatin for gallbladder cancer.
51  cancer, stage IIIA to IV, received intraabdominal cisplatin
(1 time)
Antineoplastic Agents
(1 time)
5'-DFUR (1 time)
LNT (1 time)
MMC (1 time)
2002 [Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion].
52  cancer. miRNAs have been reported to be involved in cisplatin
(1 time)
Neoplasms
(1 time)
ITGB8 (1 time)
2018 miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
53  cancer.He underwent neoadjuvant chemotherapy with cisplatin
(1 time)
Antineoplastic Agents
(1 time)
5-FU (1 time)
CT (1 time)
DCF (1 time)
2017 [Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report].
54  cancers, and is known to induce resistance to cisplatin
(1 time)
Neoplasms
(1 time)
--- 1999 Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells.
55  capacity in targeted delivery of Cisplatin
(1 time)
Natural Science Disciplines
(1 time)
CSNP (1 time)
NHBE (1 time)
PLGA (1 time)
2017 Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy.
56  carcinoma received 1-day per week administration of cisplatin
(1 time)
Neoplasms
(1 time)
CI (1 time)
CRs (1 time)
PRs (1 time)
1997 Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer.
57  carcinoma successfully treated by S-1 and cisplatin
(1 time)
Antineoplastic Agents
(1 time)
--- 2009 [A case of synchronous hepatocellular carcinoma successfully treated by S-1 and cisplatin (CDDP) as neoadjuvant chemotherapy for gastric cancer].
58  carcinoma to the liver treated with induction chemotherapy with cisplatin
(1 time)
Gastrointestinal Neoplasms
(1 time)
5-FU (1 time)
2016 A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature.
59  carcinoma were entered into a feasibility study of cisplatin
(1 time)
Neoplasms
(1 time)
--- 1991 Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma. A feasibility study.
60  carcinoma were randomized to receive cisplatin
(1 time)
Neoplasms
(1 time)
pCRs (1 time)
PFSs (1 time)
1991 Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
61  carcinomatosis of the bone marrow treated with S-1 and cisplatin
(1 time)
Antineoplastic Agents
(1 time)
DIC (1 time)
2013 [A case of gastric cancer accompanied by disseminated carcinomatosis of the bone marrow successfully controlled by S-1 and cisplatin combination therapy].
62  carcinosarcoma should be treated with adjuvant cisplatin
(1 time)
Hematology
(1 time)
DOX (1 time)
EPIDX (1 time)
IFO (1 time)
2008 The management of patients with uterine sarcoma: a debated clinical challenge.
63  cardia responding to S-1 plus cisplatin
(1 time)
Antineoplastic Agents
(1 time)
--- 2008 [A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home].
64  Cardiovascular Disease and Diabetes Prevention
(1 time)
Nursing
(1 time)
GGT DPP (1 time)
2011 Implementation of diabetes prevention programs in rural areas: Montana and south-eastern Australia compared.
65  carnitine deficiency is a risk factor during development of cisplatin
(1 time)
Pharmacology
(1 time)
ATP (1 time)
LDH (1 time)
PLC (1 time)
2006 Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model.
66  Case 1 involved a 43-year-old woman undergoing S-1/cisplatin
(1 time)
Antineoplastic Agents
(1 time)
ADL (1 time)
CT (1 time)
MRI (1 time)
2013 [Cases of three patients undergoing chemotherapy for gastric cancer who developed Trousseau's syndrome].
67  cases of definitive renal failure secondary to administration of cisplatin
(1 time)
Nephrology
(1 time)
--- 1993 [Definitive end-stage chronic kidney failure after cisplatin treatment].
68  caspase-1 activity induced after exposure to cisplatin
(1 time)
Genetics, Medical
(1 time)
--- 2000 Caspase-1 activity as a possible predictor of apoptosis induced by cisplatin in gastric cancer cells.
69  cationic hydrolysis products from the neutral parent complex
(1 time)
Chemistry Techniques, Analytical
(1 time)
LCED (1 time)
TCDCP (1 time)
1987 Determination of platinum-containing drugs in human plasma by liquid chromatography with reductive electrochemical detection.
70  caused by gamma-irradiation or cisplatin
(1 time)
Pharmacology
(1 time)
MT (1 time)
1994 Role of metallothionein in carcinogenesis.
71  CBDCA was chosen instead of cisplatin
(1 time)
General Surgery
(1 time)
DTX (1 time)
GEM (1 time)
PTX (1 time)
2009 [Experience of postoperative adjuvant chemotherapy of lung cancer at outpatient department].
72  CCC and to elucidate whether it contributes to cisplatin
(1 time)
Gynecology
(1 time)
CCC (1 time)
SAC (1 time)
2007 Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
73  CDDP and doxorubicin given at the initial chemotherapy
(1 time)
Antineoplastic Agents
(1 time)
SLL (1 time)
1990 [Evaluation of UFT administration in patients with ovarian cancer who had no evidence of disease after the initial therapy].
74  CDDP(M+) groups we used, intraoperatively, carbon nanotubes filled with cisplatin
(1 time)
Biology
(1 time)
NSS (1 time)
SWCNT (1 time)
2015 New application of carbon nanotubes in haemostatic dressing filled with anticancer substance.
75  CDDP-hydrogel
(1 time)
Pharmacology
(1 time)
PBS (1 time)
2003 In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel.
76  CDDP-resistant
(1 time)
Neoplasms
(1 time)
--- 1991 Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
77  CDDPmc,group A
(1 time)
General Surgery
(1 time)
--- 1990 [Serum concentration and distribution in the liver, lung, heart and kidney of platinum after hepatic arterial injection in the form of cis-diammine dichloroplatinum microcapsule in rabbits].
78  CEA level increased, so combination chemotherapy of S-1 and cisplatin
(1 time)
Antineoplastic Agents
(1 time)
--- 2010 [S-1-based chemotherapy for recurrent gastric cancer with peritoneal dissemination resulting in long-term survival--report of a case].
79  cell death upon exposure to DNA-damaging agents such as cisplatin
(1 time)
Molecular Biology
(1 time)
HO-1 (1 time)
2011 p53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1.
80  cell growth and enhanced sensitivity to cisplatin
(1 time)
Neoplasms
(1 time)
EBV (1 time)
LMP1 (1 time)
NPC (1 time)
2006 Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice.
81  cell lines and their sublines resistant to ADM and cisplatin
(1 time)
Neoplasms
(1 time)
ADM (1 time)
RR (1 time)
1997 Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
82  cell lines to four therapeutic drugs, including cisplatin
(1 time)
Gastroenterology
(1 time)
HCC (1 time)
2017 Mus81 knockdown sensitizes colon cancer cells to chemotherapeutic drugs by activating CHK1 pathway.
83  cells acquired fully neoplastic phenotype and resistance to Cisplatin
(1 time)
Antineoplastic Agents
(1 time)
--- 1997 [Cell signaling and CDDP resistance].
84  cells and on the growth, differentiation, apoptosis and cisplatin
(1 time)
Neoplasms
(1 time)
ATRA (1 time)
1998 Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells.
85  cells and produced anti-tumor effects by a combination of cisplatin
(1 time)
Genetics, Medical
(1 time)
Ad-p53 (1 time)
PEM (1 time)
2012 Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.
86  cells and their sensitivity to adriamycin(ADM) and cisplatin
(1 time)
Neoplasms
(1 time)
ADM (1 time)
2000 [The effect of antisense hsp90 beta on the malignant phenotype and sensitivity of HeLa cells to chemotherapeutic drugs].
87  cells and was associated with enhanced cisplatin
(1 time)
Neoplasms
(1 time)
LCSCs (1 time)
YAP (1 time)
2018 Role of YAP in lung cancer resistance to cisplatin.
88  cells during chemotherapy, F-2 cells were treated with cisplatin
(1 time)
Biochemistry
(1 time)
DOX (1 time)
LPA (1 time)
Lpar1 (1 time)
2015 LPA signaling through LPA receptors regulates cellular functions of endothelial cells treated with anticancer drugs.
89  cells from apoptosis induced by the chemotherapeutic agent cisplatin
(1 time)
Immune System Diseases
(1 time)
ASMase (1 time)
iNOS (1 time)
NO (1 time)
2018 Nitric Oxide Generated by Tumor-Associated Macrophages Is Responsible for Cancer Resistance to Cisplatin and Correlated With Syntaxin 4 and Acid Sphingomyelinase Inhibition.
90  cells induced by the chemotherapy agent cisplatin
(1 time)
Biochemistry
(1 time)
NMR (1 time)
OS (1 time)
SRV (1 time)
2010 Nuclear magnetic resonance (NMR) study of the effect of cisplatin on the metabolic profile of MG-63 osteosarcoma cells.
91  cells showed increased resistance to cisplatin
(1 time)
Neoplasms
(1 time)
CSCs (1 time)
DXR (1 time)
2013 The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics.
92  cells showed sensitivity to ICL-inducing agents such as cisplatin
(1 time)
Biochemistry
(1 time)
HR (1 time)
ICL (1 time)
KO (1 time)
2014 Tumor suppressor RecQL5 controls recombination induced by DNA crosslinking agents.
93  cells to multiple other drugs including cisplatin
(1 time)
Medicine
(1 time)
met (1 time)
TNBC (1 time)
2013 RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.
94  cells were treated with different concentrations of Pu and cisplatin
(1 time)
Neoplasms
(1 time)
Bcl-2 (1 time)
HCC (1 time)
Pu (1 time)
2017 Puerarin increases the chemosensitivity of hepatocellular carcinoma cells.
95  cells were treated with specially designated concentrations of cisplatin
(1 time)
Neoplasms
(1 time)
CSCs (1 time)
2016 Cisplatin-resistant osteosarcoma cells possess cancer stem cell properties in a mouse model.
96  cells which developed resistance to the alkylating drug cis-latinum
(1 time)
Biochemistry
(1 time)
MTX (1 time)
SqCHN (1 time)
1990 Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum.
97  cells with ATRA, for their respective doubling time, enhanced cisplatin
(1 time)
Neoplasms
(1 time)
ATRA (1 time)
EGF (1 time)
PKC (1 time)
1997 Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines.
98  cells, a decreased sensitivity to doxorubicin-, SN-38-, cisplatin
(1 time)
Molecular Biology
(1 time)
HCC (1 time)
MOC (1 time)
mtDNA (1 time)
2014 The expression of genes involved in hepatocellular carcinoma chemoresistance is affected by mitochondrial genome depletion.
99  cells, which is normally induced by cisplatin
(1 time)
Molecular Biology
(1 time)
--- 2009 Pim-1 plays a pivotal role in hypoxia-induced chemoresistance.
100  cellular and molecular interactions between TAS-106 and cisplatin
(1 time)
Neoplasms
(1 time)
--- 2009 1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo.